Webcast ImageWebcast
Q2 2016 Depomed Earnings Conference Call (Replay)
08/03/16 at 4:30 p.m. ET

Depomed is a specialty pharmaceutical company focused on pain and other central nervous system conditions. We currently market FDA-approved products, NUCYNTA®ER, NUCYNTA®, Gralise®, Cambia®, Lazanda® and Zipsor®. We actively seek to expand our product portfolio by identifying product acquisition targets that fit within our pain and neurology portfolio, have lengthy periods of exclusivity and have untapped market potential.Depomed also has successfully developed and licensed its proprietary oral drug-delivery technology, Acuform®, that allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. Depomed has licensed Acuform technology to six pharmaceutical partners, and the technology is currently being used in four marketed drugs, including NUCYNTA ER and Gralise.

The following are abbreviated descriptions of Depomed’s products:

NUCYNTA® ER (tapentadol) extended release tablets indicated, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate and in adult patients who have neuropathic pain associated with diabetic peripheral neuropathy (DPN) that is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate;

NUCYNTA® (tapentadol) an immediate release version of tapentadol, is indicated for the management of moderate to severe acute pain in adults;

Gralise® (gabapentin), a once-daily product for the management of postherpetic neuralgia, 

Cambia®(diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older,

Lazanda® (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving and who are tolerant to regular opioid therapy for their underlying persistent cancer pain, and

Zipsor® (diclofenac potassium) liquid filled capsules, a product for the treatment of mild to moderate acute pain in adults.

See Important Safety Information for Gralise and the black box warnings for NUCYNTA ER, NUCYNTA, Cambia, Lazanda and Zipsor.

Recent News> MORE
08/03/16Depomed Reports Second Quarter 2016 Financial ResultsPrinter Friendly Version
07/27/16Depomed to Report Second Quarter Fiscal Year 2016 Financial Results on Wednesday, August 3, 2016Printer Friendly Version
07/18/16Depomed Announces Patent Trial and Appeal Board Denial of Inter Partes Review of NUCYNTA PatentPrinter Friendly Version
Upcoming and Recent Events> MORE
4:30 p.m. ET
Q2 2016 Depomed Earnings Conference Call
Supporting Materials
Download Event Supporting Material Depomed Q2 2016 Earnings Conference Transcript
1:30 p.m. ET
Depomed at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
LocationNew York, NY
10:00 a.m. ET
Depomed at the JMP Securities 2016 Life Sciences Conference
LocationNew York, NY

DEPO (Common Stock)

Change (%)
 - 0.19 (0.96%)
Market Cap

Data as of 08/29/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Powered By EDGAR Online, Inc.